17 citations
,
February 2011 in “Expert Opinion on Drug Safety” Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
May 2026 in “Bioorganic Chemistry”
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
September 2021 in “Journal of the American Academy of Dermatology” CTCL patients can safely continue treatment during COVID-19 with proper safety measures.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
16 citations
,
June 2017 in “JAMA Dermatology” Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.
2 citations
,
December 2024 in “Journal of Dermatological Treatment” IL-23 inhibitors may help treat other skin conditions, but more research is needed.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
3 citations
,
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab for treating psoriasis.
October 2025 in “The American Journal of Gastroenterology” Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.
December 2020 in “Forum Dermatologicum” Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
20 citations
,
May 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Etanercept effectively treated a severe skin condition when other treatments failed.
14 citations
,
August 2015 in “Endocrinology” The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.
July 2003 in “Journal of Cutaneous Medicine and Surgery” Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.
2 citations
,
April 2019 in “Proceedings of Singapore Healthcare” Collaborative care between physicians and pharmacists improved medication management for rheumatoid arthritis without raising costs.
23 citations
,
August 1983 in “PubMed” Clq deficiency is linked to systemic lupus erythematosus symptoms.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
January 2014 in “Progress of Digestive Endoscopy” Prednisolone improved symptoms in a woman with Cronkhite-Canada syndrome, but regular screenings are needed due to cancer risk.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
June 2020 in “Annals of the Rheumatic Diseases” Patients need better information about the risks of long-term steroid use.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
July 2024 in “Journal of Investigative Dermatology”
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
September 2015 in “Photodiagnosis and Photodynamic Therapy”